Caris Life Sciences Sustainability Profile
Caris Life Sciences, a leading innovator in the field of precision medicine, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, the company has established itself as a key player in the biotechnology industry, focusing on molecular profiling and advanced diagnostics to enhance cancer treatment. Caris Life Sciences offers a range of unique services, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor therapies to individual patients. The company’s commitment to advancing personalised medicine has garnered recognition, positioning it as a trusted partner in oncology. With a robust portfolio of cutting-edge technologies, Caris Life Sciences continues to drive significant advancements in patient care and treatment outcomes.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 28 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported total carbon emissions of approximately 1,463,000,000 kg CO2e from Scope 1 and 2 combined, alongside a significant Scope 3 emission total of about 4,594,000,000 kg CO2e. This reflects a decrease from 2022, when emissions were approximately 1,760,000,000 kg CO2e for Scope 1 and 2, and about 6,680,000,000 kg CO2e for Scope 3. Despite these figures, Caris Life Sciences has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company does not appear to inherit emissions data from a parent organisation, indicating that its reported figures are solely its own. The emissions data highlights the company's substantial carbon footprint, particularly in Scope 3 emissions, which are often the most challenging to manage. As the organisation continues to navigate its climate commitments, further transparency and strategic initiatives may be necessary to address its environmental impact effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 6,680,000,000 | 0,000,000,000 |
How Carbon Intensive is Caris Life Sciences's Industry?
How Carbon Intensive is Caris Life Sciences's Location?
Caris Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Caris Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
